Dublin, July 11, 2018 (GLOBE NEWSWIRE) -- The "Pulmonary Arterial Hypertension (PAH) Therapeutics - Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering.
The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, Latin America, and Rest of World. Annual estimates and forecasts are provided for the period 2015 through 2022. Also, a six-year historic analysis is provided for these markets.
This report analyzes the worldwide markets in US$ Million.
The global market is analyzed by the following Drug Class and Brands:
- Endothelin Receptor Antagonist (Letairis/Volibris, Macitentan, Thelin, & Tracleer)
- Prostacyclin and Prostacyclin Analogs (Epoprostenol/Veletri*, Flolan, Remodulin, Selexipag, Tyvaso, Ventavis, & Orenitram)
- PDE-5 Inhibitors (Cialis/Adcirca, & Revatio)
- Soluble Guanylate Cyclase (sGC) Stimulator (Riociguat)
The report profiles 31 companies including many key and niche players such as:
- Actelion Pharmaceuticals Ltd (Switzerland)
- Bayer AG (Germany)
- Gilead Sciences, Inc. (US)
- Pfizer, Inc. (US)
- United Therapeutics Corporation (US)
- Lung Biotechnology PBC (US)
Key Topics Covered
1. INDUSTRY OVERVIEW
Pulmonary Arterial Hypertension (PAH)
A Prelude
Current & Future Analysis
PAH Drugs Market by Class
The PAH Classification
PH Patient Groupings as per World Health Organization
Classification of PAH patients as per New York Heart Association (NYHA)
Oral Therapies lead the Global PAH Therapeutics Market
Combination Therapy Favored over Monotherapy for PAH
Pediatric PAH
A Potential Market with Unmet Need
Inflammation: New Target for PAH Therapeutics
Aging Population & PAH
2. COMPETITIVE SCENARIO
Leading Players
Leading Approved Drugs as Per Mode of Administration
Major Drug Brands by Class
Prostacyclin receptor agonist/ Prostacyclin Analogue
Flolan (Epoprostenol)
Ventavis (Iloprost)
Remodulin (Treprostinil)
Orenitram
Tyvaso
Uptravi (Selexipag)
Veletri (Epoprostenol for Injection)
Phosphodiesterase 5 inhibitor
Revatio
Adcirca (Tadalafil)
Endothelin receptor antagonists (ERAs)
Opsumit
Tracleer (Bosentan)
Letairis (Ambrisentan)
Loss of Market exclusivity Tones Down Growth
Patent Expiry of Leading PAH Drugs
Opsumit & Uptravi: Game-changers for Actelion
Selexipag
Latest Entrant in PAH Therapeutics
United Therapeutics
A Major Player
Gilead Sciences
GlaxoSmithKline
Bayer
3. PAH PIPELINE
Pulmokine Investigates PDGF Receptor Pathway
Reata Pharmaceuticals Completes Phase 3 Study for Bardoxolone methyl
Eiger BioPharmaceuticals Commences Phase 2 Trials for Bestatin
Insmed Investigates INS 1009
LTT Bio-Pharma Focuses on LT-2004
Ascendis Investigates TransCon Treprostinil in a Phase I trial
Arena Initiates Phase II Trial for Ralinepeg,
TheraSilence nanoparticles Found to Reduce Pulmonary Arterial Thickness
CXA-10 to Undergo Phase II Study
Atu111 Undergoes Preclinical Trial for PH
RP5063
A NCE for PAH
SteadyMed to File NDA for Trevyent
Pluristem's PLX-PAD
Sagene Pharmaceuticals, Inc.
Select PAH Therapeutics under Pipeline: 2016
4. PRODUCT OVERVIEW
5. PRODUCT INNOVATIONS & APPROVALS
Nippon Shinyaku Receives Marketing Approval for Uptravi
Actelion to Initiate Phase III Study for Pediatric Formulation of Opsumit
Actelion Announces USFDA Approval of Uptravi
Reata Pharmaceuticals' Bardoxolone Methyl Receives Orphan Drug Designation
Actelion Receives Approval for Opsumit from Japan's MHLW
Bayer Healthcare Receives Approval for Adempas from Japan's MHLW
Silence Therapeutics Develops Gene Toolkit for PAH Research
Arena Pharmaceuticals' APD811 Receives Orphan Drug Status for PAH Treatment
Bayer's Adempas Approved for Two Rare Types of PAH
Actelion's Opsumit Receives Approval from Australia's TGA
6. RECENT INDUSTRY ACTIVITY
Arena Pharmaceuticals Initiates Phase 2 Clinical Trial for Ralinepag
Gilead Reports Top-Line Phase 2 Results for GS-4997 ( Selonsertib) in Pulmonary Arterial Hypertension (PAH)
Gilead Sciences Accelerates its PAH Portfolio
Mallinckrodt Pharmaceuticals Acquires Ikaria
Supernus Pharmaceuticals Receives US$2 million Milestone Payment from United Therapeutics
Vectura Group plc Acquires Activaero GmbH
Mast Therapeutics Completes Acquisition of Aires Pharmaceuticals
7. FOCUS ON SELECT GLOBAL PLAYERS
Actelion Pharmaceuticals Ltd (Switzerland)
Bayer AG (Germany)
Gilead Sciences, Inc. (US)
Pfizer, Inc. (US)
United Therapeutics Corporation (US)
Lung Biotechnology PBC (US)
8. GLOBAL MARKET PERSPECTIVE
Total Companies Profiled: 31 (including Divisions/Subsidiaries 33)
- The United States (18)
- Japan (3)
- Europe (10)
- France (1)
- Germany (3)
- The United Kingdom (3)
- Rest of Europe (3)
- Asia-Pacific (Excluding Japan) (1)
- Middle East (1)
For more information about this report visit https://www.researchandmarkets.com/research/hnlkq2/pulmonary?w=12